Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-07-05
2011-07-05
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07973020
ABSTRACT:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
REFERENCES:
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0058982 (2005-03-01), Han et al.
patent: 2006/0205963 (2006-09-01), Rubinstein et al.
patent: 2006/0257851 (2006-11-01), Bentwich
patent: 2007/0004664 (2007-01-01), McSwiggen et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2007/0135370 (2007-06-01), MacLachlan et al.
patent: WO 2006/050414 (2006-05-01), None
patent: WO 2007/048046 (2007-04-01), None
Examiner's First Report on Australian Patent Application No. 2008232891, Apr. 19, 2010, 3 pages.
Enterlein, S., et al., “Antiviral strategies against Nipah andEbolavirus: exploring gene silencing mechanisms to identify potential antiviral targets” Antiviral Research, Elsevier Science BV., May 1, 2006, p. A38, vol. 70, No. 1.
Geisbert T.W., et al., “Postexposure protection of guinea pigs against a lethalEbolaVirus challenge is conferred by RNA interference” Journal of Infectious Diseases, Jun. 15, 2006, pp. 1650-1657, vol. 193, No. 12.
Morris, K.V., et al., “Lentiviral-mediated delivery of siRNAs for antiviral therapy,” Gene Therapy, 2006, pp. 553-558, vol. 13.
PCT International Search Report and Written Opinion, PCT/US2008/058100, Apr. 14, 2009, 17 pages.
Elbashir, S., et al., “Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembryo lysate,” The EMBO Journal, 2001, p. 6877-6888, vol. 20, No. 23.
Soutschek, J., et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nov. 2004, Nature, vol. 432, pp. 173-178.
Vickers, T., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” The Journal of Biological Chemistry, Feb. 28, 2003, p. 7108-7118, vol. 278, No. 9.
Examination Report for European Patent Application No. EP 08744294.3, Jul. 21, 2010, 9 pages.
Enterlein, S., et al., “VP35 Knockdown InhibitsEbolaVirus Amplification and Protects against Lethal Infection in Mice,” Antimicrobial Agents and Chemotherapy, Mar. 2006, p. 984-993.
Warfield, K., et al., “Gene-Specific Countermeasures againstEbolaVirus Based on Antisense Phosphorodiamidate Morpholino Oligomers,” PLoS Pathogens, Jan. 2006, pp. 0005-0013, vol. 2, Issue 1.
Agrawal, S., et al., “Antisense oligonucleotides: towards clinical trials.” Trends in Biotechnology. Oct. 1996, vol. 14, pp. 376-387.
Bass, B., “The short answer,” Nature, May 24, 2001, pp. 428-429, vol. 411.
Elbashir, S., et al., “Analysis of gene function in somatic mammalian cells using small interfering RNAs,” Methods, 2002, pp. 199-213, vol. 26.
Elbashir, S., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture,” Nature, May 24, 2001, p. 494-498, vol. 411.
Elbashir, S., et al., “RNA Interference is Mediated by 21-and 22 Nucleotide RNAs,” Genes & Development, 2001, pp. 188-200, vol. 15.
Fire, A., “RNA-triggered Gene Silencing,” Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9.
Fire, A., et al., “Potent and Specific Genetic Interference by Double Stranded RNA inCaenorhabditis elegans,” Nature, Feb. 19, 1998, pp. 806-811, vol. 391.
Tuschl, T., “Functional genomics: RNA sets the standard,” Nature, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221.
Tuschl T., “RNA Interference and Small Interfering RNAs” Chembiochem, 2001, pp. 239-245, vol. 2.
Tuschl, T., et al., “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3.
Tuschl, T., “Mammalian RNA Interference,” RNAi, A Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295.
Tuschl, T., et al., “Targeted mRNA Degradation by Double-Stranded RNA in Vitro,” Genes & Development, 1999, pp. 3191-3197, vol. 13.
Tuschl, T., “Expanding small RNA interference,” Nature Biotechnology, May 2002, pp. 446-448, vol. 20.
Response to Communication Pursuant to Article 94(3) EPC, filed on Nov. 29, 2010, for European Patent Application No. EP08744294.3, 33 pages.
Bavari Sina
Borodovsky Anna
de Fougerolles Antonin
Novobrantseva Tatiana
Tan Pamela
Alnylam Pharmaceuticals, Inc.
Fenwick & West LLP
Gibbs Terra Cotta
McGarry Sean
The United States of America as represented by the Secretary of
LandOfFree
Compositions and methods for inhibiting expression of a gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting expression of a gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting expression of a gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2669590